This is the reason for today10 May 2024 16:22
When phase 2 is handled and the FDA's feedback resolves the needs for further investments, we can bring the partnership to the finish line".
"The partner will probably come during this year. Industry practice is that phase 2 data is usually partnered with. It may be that the partner's bidding will stretch the process, but the completion of the studies and the final investments will be left to the big pharmaceutical company."
"This is a once-in-a-lifetime opportunity for many Finnish investors. A banker from London said that it is rare to come across a biotech project where the finish line is already visible, but the odds are still there."
"From Finland, there will be a cure for cancer, for which there has been no treatment until now. With a large Finnish ownership base, this is a huge deal for the entire country, the country's economy and the people. Money in itself has not been a driving force for me, but it would be great if we could make as many Finns as possible poor or rich at the same time. There will not be another opportunity like this in our lifetime, when the investment will go directly to the increase in value produced by the phase 2 study, without amortization."
"The risks are already pretty minimal. The phase 1 studies showed that the drug is safe and already at that stage the drug had strong efficacy figures. If phase 2 continues to show good results, the chance of failure is already statistically very small."
"Funding should be resolved by the middle of next year. The partner deal is hanging a bit in the air all the time, but do we want to accept the first offer? An additional loan is a possibility. In addition, we can make a directed offering. For example, 10–15 million euros would be enough for the end of the year," says Jalkanen.
"We have said it publicly, that a large public share issue is also available, with which money could be raised well into next year. Several options can be used from the toolbox."
From trauma kinesis:
"It is still a good precision medicine in virus pandemics like corona. There will be a second and a third. During Corona, we were too small an operator. Big players could invest hundreds of millions and we were left behind." Finnish Financial Magazine Arvopaperi. 10.5.2024. Text by Google translate, so there might be some errors on translations..